Cd25+ T cell depletion impairs murine squamous cell carcinoma development via modulation of antitumor immune responses

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 902-909

  Ramos, Rodrigo Nalio ^a   Oliveira, Carine Ervolino ^a   Gasparoto, Thais Helena ^a   Malaspina, Tatiana Salles de Souza ^a   Belai, Eduardo Bertoli ^a   Cavassani, Karen Angélica ^b   Garlet, Gustavo Pompermaier ^a   da Silva, João Santana ^a   Campanelli, Ana Paula ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BASILIXIMAB; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; T CELL DEPLETION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84859611711     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs103     Document Type: Article

References (49)

1. Hald, J. et al. (1994) In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumor-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immunol. Immunother., 39, 383-390.
2. Hald, J. et al. (1995) Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol. Immunother., 41, 243-250.
3. Bradburn, J. E. et al. (2007) The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells. Anticancer Res., 27, 3819-3827.
4. Gasparoto, T. H. et al. (2010) Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol. Immunother., 59, 819-828.
5. + regulatory T cells in the human immune system. Nat. Rev. Immunol., 10, 490-500.
6. +) regulatory T cells. Nat. Rev. Immunol., 11, 119-130.
7. Du, C. et al. (2011) The immunoregulatory mechanisms of carcinoma for its survival and development. J. Exp. Clin. Cancer Res., 30, 12.
8. Hobeika, A. C. et al. (2011) Depletion of human regulatory T cells. Methods Mol. Biol., 707, 219-231.
9. Zou, W. (2005) Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer, 5, 263-274.
10. +T-cell-dependent immune defense of B16 melanoma. Cancer Res., 61, 8643-8646.
11. + T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J. Infect. Dis., 193, 1313-1322.
12. Cavassani, K. A. et al. (2006) Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. J. Immunol., 177, 5811-5818.
13. + regulatory T cells. J. Exp. Med., 202, 885-891.
14. + regulatory T cells. J. Immunol., 174, 90-98.
15. + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res., 13, 4345-4354.
16. Zou, W. (2006) Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol., 6, 295-307.
17. Chamoto, K. et al. (2010) 3-Methylcholanthrene-induced transforming growth factor-b-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy. Cancer Sci., 101, 855-861.
18. + T cells. Eur. J. Immunol., 39, 241-253.
19. Yamaguchi, T. et al. (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol., 16, 115-123.
20. Dunn, G. P. et al. (2006) Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol., 6, 836-848.
21. Cavassani, K. A. et al. (2010) The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood, 115, 4403-4411.
22. + T regulatory cells. J. Immunol., 17, 3301-3305.
23. + regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol., 13, 1252-1258.
24. + regulatory T cells leads to tumour rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol., 13, 613-620.
25. Bopp, T. et al. (2010) New strategies for the manipulation of adaptive immune responses. Cancer Immunol. Immunother., 59, 1443-1448.
26. Vignali, D. A. et al. (2008) How regulatory T cells work. Nat. Rev. Immunol., 8, 523-532.
27. Biswas, S. K. et al. (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol., 11, 889-896.
28. Mantovani, A. et al. (2009) Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol., 70, 325-330.
29. Siveen, K. S. et al. (2009) Role of macrophages in tumour progression. Immunol. Lett., 123, 97-102.
30. Solinas, G. et al. (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol., 86, 1065-1073.
31. Lowenthal, J. W. et al. (1985) High and low affinity IL-2 receptors: analysis by IL-2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol., 6, 3988-3994.
32. Taniguchi, T. et al. (1993) The IL-2/IL-2 receptor system: a current overview. Cell, 73, 5-8.
33. + regulatory T cells in liver transplant tolerance. Transplant Proc., 10, 3205-3256.
34. + regulatory T cells in mice infected with the filarial parasite Brugia malayi. J Immunol., 9, 6456-6466.
35. + phagocytes. Eur. J. Immunol., 3, 780-786.
36. Balkwill, F. (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer, 9, 361-371.
37. +) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck, 33, 1301-1308.
38. Zou, W. et al. (2010) T(H)17 cells in tumor immunity and immunotherapy. Nat. Rev. Immunol., 10, 248-256.
39. Teng, M. W. et al. (2010) IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc. Natl Acad. Sci. USA, 107, 8328-8333.
40. Wang, L. et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med., 206, 1457-1464.
41. Kioi, M. et al. (2009) IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int. J. Cancer, 124, 1440-1448.
42. Wang, L. et al. (2010) IL-17 enhances tumor development in carcinogeninduced skin cancer. Cancer Res., 70, 10112-10120.
43. Martinon, F. et al. (2009) The inflammasomes: guardians of the body. Annu. Rev. Immunol., 27, 229-265.
44. Demaria, S. et al. (2010) Cancer and inflammation: promise for biologic therapy. J. Immunother., 33, 335-351.
45. Liu, A. et al. (2005) Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin. Cancer Res., 11, 8492-8502.
46. + regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load. Immunol. Cell Biol., 84, 467-474.
47. Richmond, A. (2002) Nf-kappa B, chemokine gene transcription and tumour growth. Nat. Rev. Immunol., 2, 664-674.
48. Aggarwal, B. B. (2009) Inflammation, a silent killer in cancer is not so silent!. Curr. Opin. Pharmacol., 9, 347-350.
49. Gonda, T. A. et al. (2009) Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle, 8, 2005-2013.